Larazotide

Overview

Larazotide, also known by the research designation AT-1001, is an orally administered peptide that has been investigated as a potential treatment for celiac disease. Unlike most peptide therapeutics, it is designed to act locally within the gut rather than being absorbed into the bloodstream, and it is taken by mouth rather than injected.

Celiac disease is an autoimmune condition in which gluten triggers intestinal damage. The only established management is a strict gluten-free diet, which is difficult to maintain and does not always fully control symptoms. Larazotide was developed with the goal of helping patients who still experience problems despite avoiding gluten.

It is important to state clearly that larazotide is investigational. It has not been approved by the FDA or other regulators, and despite reaching advanced clinical testing, it has not become an available medicine. Its history illustrates both the promise and the difficulty of developing the first drug therapy for celiac disease.

How it works

Larazotide is described as a tight-junction regulator. Tight junctions are the sealing structures between the cells lining the intestine, and they control how much passes between the gut and the rest of the body. When these junctions become too permeable (sometimes called leaky gut), substances that should stay in the intestine may cross the barrier and provoke immune responses.

The peptide is thought to act on the zonulin pathway, a signaling system involved in regulating intestinal permeability. In celiac disease, gluten exposure is associated with increased permeability, and larazotide is intended to help keep tight junctions closed, reducing the passage of gluten fragments that drive inflammation.

By tightening the intestinal barrier rather than altering the immune system broadly or breaking down gluten, larazotide represents a targeted approach. Because it is meant to work at the gut surface and is minimally absorbed, the strategy aims to act where the damage begins while limiting systemic exposure.

Research & evidence

Larazotide advanced further in clinical development than most experimental celiac therapies, reaching phase 3 testing as an add-on to a gluten-free diet for patients with persistent symptoms. Earlier-phase studies had suggested it might reduce symptoms, generating considerable interest because no approved drug exists for the condition.

However, the pivotal late-stage program did not meet its primary endpoint, meaning the trial failed to demonstrate the predefined benefit needed to support approval. This outcome was a significant setback and is the reason larazotide is not an available treatment despite years of development.

The larazotide story is a useful reminder that promising early results do not guarantee success in larger, rigorous trials. Celiac disease has proven a challenging target, partly because of the difficulty in measuring symptoms objectively. Research into tight-junction modulation and other approaches continues, but at present the evidence does not support larazotide as a proven therapy.

Safety & legal status

In clinical trials, larazotide was generally reported to be well tolerated, which is consistent with its design as a minimally absorbed peptide acting locally in the gut. Reported side effects in studies were typically mild and gastrointestinal in nature, though a full safety profile can only be established through completed, approved development, which has not occurred.

Legally, larazotide is an investigational compound. It is not approved by the FDA or other regulators and is not available as a prescription medicine. Its use has been confined to clinical research settings under regulatory oversight, not general medical practice.

Because it is not approved, larazotide should not be confused with available celiac treatments, of which there are none in drug form, since a gluten-free diet remains the standard of care. Any product marketed to consumers under this name outside of a sanctioned clinical trial would fall outside the regulated framework, and patients with celiac disease should rely on qualified medical guidance rather than unproven offerings.

Frequently asked questions

References

Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.

1. Leffler DA, Kelly CP, Green PH, et al. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. Gastroenterology. 2015. Peer-reviewed study
2. Slifer ZM, Krishnan BR, Madan J, Blikslager AT. Larazotide acetate: a pharmacological peptide approach to tight junction regulation. Am J Physiol Gastrointest Liver Physiol. 2021. Peer-reviewed study
3. Troisi J, Venutolo G, Terracciano C, et al. The Therapeutic use of the Zonulin Inhibitor AT-1001 (Larazotide) for a Variety of Acute and Chronic Inflammatory Diseases. Curr Med Chem. 2021. Peer-reviewed study
4. Hoilat GJ, Altowairqi AK, Ayas MF, et al. Larazotide acetate for treatment of celiac disease: A systematic review and meta-analysis of randomized controlled trials. Clin Res Hepatol Gastroenterol. 2022. Peer-reviewed study
5. Huang YC, Chiang Chiau JS, Cheng ML, et al. Preventive effects of Larazotide acetate (AT-1001) on non-alcoholic fatty liver diseases (NAFLD) in a mouse model. Pediatr Neonatol. 2026. Peer-reviewed study
6. Slifer ZM, Hernandez L, Pridgen TA, et al. Larazotide acetate induces recovery of ischemia-injured porcine jejunum via repair of tight junctions. PLoS One. 2021. Peer-reviewed study